High-dose ecabet sodium improves the eradication rate of helicobacter pylori in dual therapy with lansoprazole and amoxicillin.
OBJECTIVE
The additive effect of ecabet sodium in combination with dual therapy on Helicobacter pylori eradication was evaluated.


METHODS
H. pylori-positive chronic gastritis patients were randomly assigned to one of the following three groups and medicated for 2 weeks. Group LA: dual therapy (lansoprazole 30 mg o.d. plus amoxicillin 750 mg b.d.). Group LA1E: dual therapy plus ecabet sodium (1 g b.d.). Group LA2E: dual therapy plus ecabet sodium (2 g b.d.). Patients were evaluated 4 weeks after the cessation of treatment by culture and 13C-urea breath test.


RESULTS
Seventy-one patients (mean age, 56.6 years; range, 26-79 years; 40 males, 31 females) were enrolled in this prospective, single-blind study, and 68 completed the protocol. The eradication rates per protocol patient were 43% in group LA, 62% in group LA1E, and 79% in group LA2E, and those on the intention-to-treat basis were 42% in group LA, 57% in group LA1E and 79% in group LA2E. The eradication rate in group LA2E was significantly higher than group LA (P=0.032 in per protocol, P=0.022 in intention-to-treat). Adverse effects were observed in 10 patients in this study. There were no severe adverse effects caused by ecabet sodium.


CONCLUSIONS
High-dose ecabet sodium increases eradication rates of H. pylori in dual therapy with lansoprazole and amoxicillin.
Kagaya
H
H
Department of Gastroenterolgy and Hematology, Hokkaido University, Graduate School of Medicine, Sapporo, Japan. hikagaya@med.hokudai.ac.jp
Kato
M
M
Komatsu
Y
Y
Mizushima
T
T
Sukegawa
M
M
Nishikawa
K
K
Hokari
K
K
Takeda
H
H
Sugiyama
T
T
Asaka
M
M
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D045784:Abietanes; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004224:Diterpenes / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010406:Penicillins / Q000627:therapeutic use*; D016037:Single-Blind Method; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D045784:Abietanes; D000897:Anti-Ulcer Agents; D004224:Diterpenes; D010406:Penicillins; D064747:Lansoprazole; C061681:ecabet; D000658:Amoxicillin; D009853:Omeprazole